TY - JOUR
T1 - Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America
AU - Palmu, Arto A.
AU - De Wals, Philippe
AU - Toropainen, Maija
AU - Ladhani, Shamez N.
AU - Deceuninck, Geneviève
AU - Knol, Mirjam J.
AU - Sanders, Elisabeth A.M.
AU - Miller, Elizabeth
N1 - Funding Information:
AAP and MT report grants from GlaxoSmithKline, Pfizer, and Sanofi to the Finnish Institute for Health and Welfare for research projects in which they are investigators. PDW received research grants from GSK, Pfizer and Sanofi. SNL performs contract work on behalf of St. George’s University of London for pharmaceutical companies, including vaccine manufacturers but does not receive any personal remuneration. EAMS reports grant from GlaxoSmithKline and Pfizer to the University Medical Center Utrecht for research projects in which she was an investigator. All other authors declare no competing interests.
Publisher Copyright:
© 2021
PY - 2021/3/12
Y1 - 2021/3/12
N2 - High incidence of childhood invasive pneumococcal disease (IPD) in the US declined steeply after 7-valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing reductions observed elsewhere. We re-analysed aggregate published data and compared pre- and post-PCV IPD-incidence in different countries to explore PCV impact on hospitalised and outpatient IPD separately. The proportion of hospitalised IPD cases was consistently high (>80%) in England&Wales, Finland, the Netherlands, and Quebec/Canada, but only 32% in the US before PCV introduction, increasing to 69% during the PCV era. In the US, a higher reduction in outpatient IPD incidence (94% in 2015 versus 1998–99) was observed compared to hospitalised IPD (79%); a 51% reduction in the non-PCV13-type IPD incidence among outpatient cases was estimated compared to a >2-fold increase for hospitalised cases. After stratification by hospitalization status, PCV programmes resulted in similar impact and serotype replacement in hospitalised IPD in US when compared to other countries.
AB - High incidence of childhood invasive pneumococcal disease (IPD) in the US declined steeply after 7-valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing reductions observed elsewhere. We re-analysed aggregate published data and compared pre- and post-PCV IPD-incidence in different countries to explore PCV impact on hospitalised and outpatient IPD separately. The proportion of hospitalised IPD cases was consistently high (>80%) in England&Wales, Finland, the Netherlands, and Quebec/Canada, but only 32% in the US before PCV introduction, increasing to 69% during the PCV era. In the US, a higher reduction in outpatient IPD incidence (94% in 2015 versus 1998–99) was observed compared to hospitalised IPD (79%); a 51% reduction in the non-PCV13-type IPD incidence among outpatient cases was estimated compared to a >2-fold increase for hospitalised cases. After stratification by hospitalization status, PCV programmes resulted in similar impact and serotype replacement in hospitalised IPD in US when compared to other countries.
KW - Bias
KW - Conjugate vaccines
KW - Streptococcus pneumoniae
KW - Surveillance
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85101396398&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.01.070
DO - 10.1016/j.vaccine.2021.01.070
M3 - Article
C2 - 33610373
AN - SCOPUS:85101396398
SN - 0264-410X
VL - 39
SP - 1551
EP - 1555
JO - Vaccine
JF - Vaccine
IS - 11
ER -